Table 4.
Face-to-face contact rates and drug prescription rates since breast cancer diagnosis by characteristics of women with breast cancer (n = 185)
| Univariate | Multivariate | |||
|---|---|---|---|---|
| ≤ Median | > Median | OR (CI) | OR (CI) | |
| Outcome: annual face-to-face contact rate since diagnosis | n = 100 | n = 85 | ||
| Face-to-face contact rate before diagnosis, n (%) | ||||
| ≤ Median | 61 (61.0) | 32 (37.6) | 1 | |
| > Median | 39 (39.0) | 53 (62.4) | 2.59 (1.43–4.70)** | |
| General practice, n (%) | ||||
| Groningen | 41 (41.0) | 23 (27.1) | 1 | |
| Hoogeveen | 27 (27.0) | 28 (32.9) | 1.85 (0.89–3.86) | |
| Sappemeer | 32 (32.0) | 34 (40.0) | 1.89 (0.94–3.82) | |
| Age at diagnosis, n (%) | ||||
| ≤ Median | 55 (55.0) | 38 (44.7) | 1 | |
| > Median | 45 (45.0) | 47 (55.3) | 1.51 (0.85–2.70) | |
| T stage, n (%) | ||||
| Tis/T1 | 61 (63.5) | 37 (47.2) | 1 | |
| T2/T3/T4 | 35 (36.5) | 41 (52.6) | 1.93 (1.05–3.55)* | |
| N stage, n (%) | ||||
| N0 | 63 (64.3) | 49 (60.5) | 1 | |
| N+ | 35 (35.7) | 32 (39.5) | 1.18 (0.64–2.16) | |
| Surgery, n (%) | ||||
| Lumpectomya | 58 (59.2) | 37 (44.0) | 1 | |
| Mastectomyb | 40 (40.8) | 47 (56.0) | 1.86 (1.03–3.37)* | |
| Chemotherapy, n (%) | ||||
| No | 65 (65.0) | 56 (65.9) | 1 | |
| Yes | 35 (35.0) | 29 (34.1) | 0.96 (0.52–1.77) | |
| Endocrine therapy, n (%) | ||||
| No | 65 (65.0) | 40 (47.1) | 1 | |
| Yes | 35 (35.0) | 45 (52.9) | 2.09 (1.16–3.78)* | |
| Outcome: annual drug prescription rate since diagnosis | n = 95 | n = 90 | ||
| Drug prescription rate before diagnosis, n (%)* | ||||
| ≤ Median | 80 (84.2) | 17 (18.9) | 1 | 1 |
| > Median | 15 (15.8) | 73 (81.1) | 22.90 (10.67–49.14)*** | 23.23 (10.14–53.22)*** |
| General practice, n (%)* | ||||
| Groningen | 41 (43.2) | 23 (25.6) | 1 | 1 |
| Hoogeveen | 21 (22.1) | 34 (37.8) | 2.89 (1.37–6.09)** | 4.09 (1.49–11.24)** |
| Sappemeer | 33 (34.7) | 33 (36.7) | 1.78 (0.88–3.60) | 1.56 (0.60–4.04) |
| Age at diagnosis, n (%)* | ||||
| ≤ Median | 59 (62.1) | 34 (37.8) | 1 | 1 |
| > Median | 36 (37.9) | 56 (62.2) | 2.70 (1.49–4.89)** | 1.50 (0.66–3.40) |
| T stage, n (%) | ||||
| Tis/T1 | 53 (57.0) | 45 (55.6) | 1 | |
| T2/T3/T4 | 40 (43.0) | 36 (44.4) | 1.06 (0.58–1.93) | |
| N stage, n (%) | ||||
| N0 | 58 (61.7) | 54 (63.5) | 1 | |
| N+ | 36 (38.3) | 31 (36.5) | 0.92 (0.50–1.70) | |
| Surgery, n (%) | ||||
| Lumpectomya | 52 (55.3) | 43 (48.9) | 1 | |
| Mastectomyb | 42 (44.7) | 45 (51.1) | 1.36 (0.76–2.44) | |
| Chemotherapy, n (%) | ||||
| No | 58 (61.1) | 63 (70.0) | 1 | |
| Yes | 37 (38.9) | 27 (30.0) | 0.76 (0.36–1.24) | |
| Endocrine therapy, n (%) | ||||
| No | 59 (62.1) | 46 (51.1) | 1 | |
| Yes | 36 (37.9) | 44 (48.9) | 1.57 (0.87–2.81) | |
Univariate analysis, odds ratios (OR) and 95% confidence intervals (95% CI) estimated with multivariate logistic regression analysis
Significant at *p < 0.05, **p < 0.01 and ***p < 0.001
aIncluding patients treated with lumpectomy, with and without radiation therapy
bIncluding patients treated with lumpectomy followed by mastectomy, with and without radiation therapy